Skip to main content
LFMD logo

LifeMD, Inc. (LFMD) Stock: Price, Forecast & Analyst Target

LifeMD, Inc. (LFMD) — MoonshotScore 23/100 (Weak band), calculated Nov 18, 2026. Price $1.59 (-6.18%), as of the Nov 19, 2026 trading session; market cap $77.1M.

Educational signal · not a buy or sell recommendation · How to read this

$1.59 −$0.105 (-6.18%) Market Cap $77.1M

LifeMD, Inc. · LFMD · NASDAQ

LifeMD, Inc. is a direct-to-patient telehealth company that connects consumers to healthcare professionals. It offers virtual medical treatment and prescription medications across various indications, including men's sexual health, dermatology, and primary care.

Price as of Nov 19, 2026

Key Statistics

23 of 100

MoonshotScore v2 · LifeMD (LFMD)

Weak
Business Quality Average (59)
Financial Safety Fragile (13)
Valuation Fair (73)
Growth Durability Fading (20)
Momentum Slipping (28)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A fragile balance sheet and stalling growth, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Average; Financial Safety: Fragile; Valuation: Fair; Growth Durability: Fading; Momentum: Slipping.

  • quarterly revenue $48M (Q3 FY2025, quarter ended Sep 2025)
  • EPS beat 0 of the last 4 reports
  • Altman Z -3.08 · Piotroski F 2

Holding back: balance-sheet strain, soft growth, weak price trend

Helping: an attractive price

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for LFMD (57 recorded, newest six shown)
RecordedScoreBand
22Weak
24Weak
23Weak
23Weak
23Weak
23Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$1.59
Change on the day-6.18%
Market capitalisation$77.1M—
Shares traded on the day1.24M

Price & events

Other perspectives

Council score for LifeMD (LFMD): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Neutral
Financial Safety Negative
Valuation Moderate
Growth Durability Weak
Momentum Weak

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Neutral read

Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation

Financial Health Negative
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Strong
ROE Negative
Gross Margin Strong

Read on: Nov 19, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is LifeMD (LFMD), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. LifeMD, Inc. (LFMD) is listed on NASDAQ. It employs 347 people. In Q3 FY2025 it reported revenue of $48M and net income of -$4M. The market values it at $77.1M.

2 · Latest results

What do the latest results show for LifeMD (LFMD)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of $48M. Against analyst estimates the company has EPS beat 0 of the last 4 reports.

Quarterly income statement — 2 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2025$48M-$4M-$0.10 (diluted)
Q4 FY2025$7M$20M$0.41 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for LifeMD (LFMD)?

Short answer

The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is balance-sheet strain, soft growth, weak price trend. The distress and quality screens read Altman Z -3.08 · Piotroski F 2. Trailing ratios: ROA -19.8% · current ratio 0.80.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -3.08 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 2 of the last 4 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at LifeMD (LFMD)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $192.45M · EPS -0.60 · 4 analysts. Current published price targets run low $5.00 · high $9.00 · consensus $7.00 · median $7.00 against a quoted price of $1.59 (as of Nov 19, 2026).

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • The newest quarter held here (Q3 FY2025) was filed Nov 17, 2025 — 11 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does LifeMD compare with its peers?

Short answer

LifeMD's score ranks 2nd of 4 in the bounded comparison shown, against 3 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
CVS Health Corporation (CVS) Named competitor$80.06 Nov 19, 2026$102B81 5-pillar Nov 18, 2026
LifeMD (LFMD) — this page$1.59$77.1M23
American Well Corporation (AMWL) Named competitor$10.69 Nov 19, 2026$184M20 5-pillar Nov 18, 2026
Teladoc Health, Inc. (TDOC) Named competitor$7.79 Nov 19, 2026$1.42B16 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$5.00 – $9.00
Consensus target
$7.00
Median target
$7.00
Revenue estimate
$192.45M
EPS estimate
$-0.60

Consensus record · Captured .

Measured against a quoted price of $1.59 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Aug 11, 2026

Transactions
6
Identified insiders
6
Purchases
0
Sales
0
Other transactions
6

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held LFMD in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported LFMD in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about LifeMD (LFMD)?

Read these with our analysis →

What Investors Ask About LifeMD (LFMD)

These answers are editorial: 1 of these 9 answers is drawn from the LFMD research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for LFMD?

LFMD carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. LifeMD, Inc. is a direct-to-patient telehealth company that connects consumers to healthcare professionals.

Is LFMD a good stock to buy?

Stock Expert AI does not rate LFMD buy, sell or hold. LifeMD, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the LFMD stock price today?

The last price recorded for LifeMD, Inc. (LFMD), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the LFMD price target?

The analyst consensus price target for LifeMD, Inc. (LFMD), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What do analysts say about LFMD stock?

Analyst coverage of LifeMD, Inc. (LFMD) is limited, but the general sentiment reflects cautious optimism regarding the company's growth potential in the telehealth market. Key valuation metrics, such as price-to-sales ratio, are considered in relation to the company's revenue growth rate and gross margin.

What are the key factors to evaluate for LFMD?

LifeMD, Inc. (LFMD) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. LifeMD offers a range of telehealth brands, including ShapiroMD for hair loss, RexMD for men's health, and LifeMD Primary Care for virtual primary care. Not financial advice.

How frequently does LFMD data refresh on this page?

LFMD's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven LFMD's recent stock price performance?

LifeMD, Inc. (LFMD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse portfolio of telehealth brands catering to various health needs. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider LFMD overvalued or undervalued right now?

LifeMD, Inc. (LFMD) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 21 figures on this page — 14 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.